## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re:

Application of:

Stefan ROSEWICZ, et al.

Serial No.:

To Be Assigned

International Appl. No.:

PCT/EP2005/003161

International Filing Date:

March 24, 2005

For:

**USES OF GALECTIN-2** 

MAIL STOP: PCT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

September 19, 2006

## **INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with the provisions of 37 C.F.R. § 1.97, Applicants hereby make of record the documents listed on the accompanying Form PTO-1449 for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the non-U.S. patent references, which were cited in the International Search Report in the above-identified international application, are enclosed herewith, along with a copy of the International Search Report.

If any additional fees are deemed to be due at this time, the Commissioner is authorized to charge payment of the same to Deposit Account No. 50-0552.

Respectfully Submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

Bv:

Morey B. Wildes

Reg. No. \$6,968

Davidson, Davidson & Kappel, LLC 485 Seventh Avenue, 14th Floor New York, NY 10018(212) 736-1940 10/593533 1AP9/Rec'd PCT/PT0 19 SEP 2006 PTO/SB/08a (08-03) 11S Petent and Tendemon's Office HS DEPARTMENT OF COMMISSION

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	e for form 1449A/PTC	)		Complete if Known			
				Application Number	To Be Assigned		
INFO	RMATION	DIS	CLOSURE	Filing Date	Herewith		
STA	<b>TEMENT B</b>	Y A	PPLICANT	First Named Inventor	Stefan ROSEWICZ, et al.		
				Art Unit	Not Yet Known		
(Use as many sheets as necessary)				Examiner Name	Not Yet Known		
Sheet	1	of	2	Attorney Docket Number	833.1005		

U.S. PATENT DOCUMENTS							
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevan		
Initials *	No.1	Number - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear		
		US- 2004/023855 A1	02-05-2004	John, et al.			
		US-					
		US-					
		US-	-				
		US-					
		US-					
		US-	· · · · · · · · · · · · · · · · · · ·				
		US-					
		US-					
		US-					
		US-	-				
		US-					
		US-					
		US-					
		US-					
		US-					
· · ·		US-					
•		US-					
	1	US-					
		US-					

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				Т <sup>6</sup>			
		WO 02/089831 A1	11-14-2002	Protegene Inc.					
	<u> </u>								
	<u> </u>								

Examiner Signature	Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10/593533 IAP9/Rec'd PCT/PTO 19 SEP 2006.

PTO/SB/08b(08-03) Approved for use through 07/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute	for form 1449B/PTO	)		Complete if Known		
INICO	DRAKTION	DIC	CL OCUDE	Application Number	To Be Assigned	
		_	CLOSURE	Filing Date	Herewith	
STAT	LEMENT B	Y A	PPLICANT	First Named Inventor	Stefan ROSEWICZ, et al.	
				Art Unit	Not Yet Known	
(Use as many sheets as necessary)				Examiner Name		
Sheet	2	of	2	Attorney Docket Number	833.1005	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>			
•		"GALECTINS: A FAMILY OF ANIMAL SS-GALACTOSIDE-BINDING LECTINS, CELL, Vol. 76, pp. 597-598, February 25, 1994				
		LIU FU-TONG: "GALECTINS: A new family of regulators of inflammation", CLINICAL IMMUNOLOGY, Vol. 97, no. 2, pp. 79-88, November 2000.				
		BAUM LINDA G ET AL: "Amelioration of graft versus host disease by galectin-1", Clinical Immunology, Vol. 109, no. 3, December 2003, pages 295-307.				
		EMMANOUILIDES C ET AL: "Prevention of experimental acute GVHD with galectin-1 and effects on immunologic reconstitution", BLOOD, vol. 90, no. 10 SUPPL. 1 PART 1, 15 November 1997, page 205A.				
. =		DELIOUKINA MARIA L ET AL: "Galectin-1 ameliorates the development and severity of GVHD in a murine model," BLOOD, vol. 94, no. 10 SUPPL. 1 PART 1, 15 November 1991, page 392A.				
		PERILLO N L ET AL: APOPTOSIS OF T CELLS MEDIATED BY GALECTIN-1", NATURE, vol. 378, no. 6558, pp. 736-739, 14 December 1995.				

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.